Ram Chandra, DO
Family Medicine · Odessa, MONPI 1750349874
Payments from drug & device makers
Across 116 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$354
- AstraZeneca$250
- Novo Nordisk$219
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$154
- Amgen$135
- Lilly USA, LLC$130
- plus $775 from 15 others
What the payments were for
- Food & beverage$2,016100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 20 | $354 |
| AstraZeneca | 15 | $250 |
| Novo Nordisk | 13 | $219 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 13 | $154 |
| Amgen | 9 | $135 |
| Lilly USA, LLC | 7 | $130 |
| Vanda Pharmaceuticals Inc. | 3 | $108 |
| Teva Pharmaceuticals USA, Inc. | 5 | $88 |
| Axsome Therapeutics, Inc. | 5 | $85 |
| Dexcom, Inc. | 3 | $81 |
| AbbVie | 3 | $79 |
| Novartis | 4 | $72 |
| Pfizer | 4 | $57 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| E.r. Squibb & Sons, L.L.C. | 3 | $45 |
| Sanofi-aventis U.S. LLC | 2 | $26 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Melinta Therapeutics, LLC | 1 | $11 |
How this compares
$2,016 in reported general payments places this provider in the 75th percentile of 2,203 family medicine providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AustedoDeutetrabenazine | 23 | $161,272 |
| EliquisApixaban | 342 | $129,676 |
| OzempicSemaglutide | 108 | $128,989 |
| Invega SustennaPaliperidone Palmitate | 38 | $125,291 |
| JardianceEmpagliflozin | 169 | $124,294 |
| Tetrabenazine | 22 | $99,621 |
| XareltoRivaroxaban | 129 | $65,642 |
| Tresiba Flextouch U-100Insulin Degludec | 111 | $62,552 |
| LatudaLurasidone Hcl | 22 | $47,975 |
| TrulicityDulaglutide | 35 | $44,163 |
| MounjaroTirzepatide | 37 | $43,368 |
| JanuviaSitagliptin Phosphate | 90 | $37,356 |
| MyrbetriqMirabegron | 80 | $27,144 |
| VraylarCariprazine Hcl | 17 | $24,440 |
| FarxigaDapagliflozin Propanediol | 60 | $24,105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo | $88 | $161,27223 claims |
| PfizerEliquis, Abrysvo | $57 | $145,739393 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $14 | $135,565187 claims |
| Novo NordiskOzempic | $219 | $128,989108 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $130 | $87,53172 claims |
| AbbVieVraylar, Linzess, Restasis | $79 | $46,16553 claims |
| AstraZenecaFarxiga, Symbicort | $250 | $32,54281 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $19 | $16,92165 claims |
| NovartisEntresto | $72 | $12,98919 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $354 | $8,21113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,203 family medicine providers in Missouri.
Other family medicine in Odessa
- Timothy JenningsMaryland Heights$30.2M
- William HowittSpringfield$19.9M
- Rupal TrivediSaint Louis$10.6M
- Frederic PraterMaryland Heights$9.1M
- Leea ReedRogersville$7.9M
- Dennis MorrisonSpringfield$5.7M
- Luke van KirkSpringfield$5.6M
- Amy RobertsTown And Country$4M
- Scott KuennenKansas City$2.2M
- George CarrJefferson City$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.